Statin therapy is not associated with improved outcomes after heart transplantation in children and adolescents

详细信息    查看全文

• 作者：Steven C. Greenway ; MS ; MD ; FRCPC^a ; ^{steven.greenway@albertahealthservices.ca" class="auth_mail" title="E-mail the corresponding author} ; Ryan Butts ; MD^b ; David C. Naftel ; PhD^c ; Elizabeth Pruitt ; MSPH^c ; James K. Kirklin ; MD^c ; Ingrid Larsen ; BScN^a ; Simon Urschel ; MD^a ; Kenneth Knecht ; MD^d ; Yuk Law ; MD^e
• 关键词：pediatric heart transplantation ; rejection ; vasculopathy ; statin ; HMG-CoA reductase inhibitors ; PTLD
• 刊名：Journal of Heart and Lung Transplantation
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：35
• 期：4
• 页码：457-465
• 全文大小：1028 K

文摘

Although used routinely, the pleiotropic benefits of statins remain understudied in children after heart transplantation. We hypothesized that statin therapy would reduce the incidence of rejection, cardiac allograft vasculopathy (CAV) and post-transplant lymphoproliferative disease (PTLD).

Methods

This study was a retrospective review of 964 pediatric (ages 5 to 18 years) heart transplant recipients in the multicenter Pediatric Heart Transplant Study registry from 2001 to 2012. Patients were excluded if they were undergoing re-transplantation, survived <1 year post-transplant, or had missing data regarding statin use. The effects of statins beyond the first year were estimated by Kaplan-Meier and Cox regression multivariable analysis for freedom from PTLD, rejection requiring treatment, any severity of CAV, and survival.

Results

Statin use was variable among participating centers with only 30% to 35% of patients ≥10 years of age started on a statin at <1 year post-transplant. After the first year post-transplant, statin-treated children (average age at transplant 13.24 ± 3.29 years) had significantly earlier rejection (HR 1.42, 95% CI 1.11 to 1.82, p = 0.006) compared with untreated children (transplanted at 12 ± 3.64 years) after adjusting for conventional risk factors for rejection. Freedom from PTLD, CAV and overall survival up to 5 years post-transplant were not affected by statin use, although the number of events was small.

Conclusions

Statin therapy did not confer a survival benefit and was not associated with delayed onset of PTLD or CAV. Early (<1 year post-transplant) statin therapy was associated with increased later frequency of rejection. These findings suggest that a prospective trial evaluating statin therapy in pediatric heart transplant recipients is warranted.